Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Amy Yule, M.D.

Co-Author

This page shows the publications co-authored by Amy Yule and Stephen Faraone.
Connection Strength

1.204
  1. High Correspondence Between Child Behavior Checklist Rule Breaking Behavior Scale with Conduct Disorder in Males and Females. Child Psychiatry Hum Dev. 2020 12; 51(6):978-985.
    View in: PubMed
    Score: 0.234
  2. Further Evidence of the Diagnostic Utility of the Child Behavior Checklist for Identifying Pediatric Bipolar I Disorder. Scand J Child Adolesc Psychiatr Psychol. 2019; 7(1):29-36.
    View in: PubMed
    Score: 0.211
  3. Examining the association between attention deficit hyperactivity disorder and substance use disorders: A familial risk analysis. J Psychiatr Res. 2017 02; 85:49-55.
    View in: PubMed
    Score: 0.176
  4. Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder. J Clin Psychiatry. 2016 Oct; 77(10):1420-1427.
    View in: PubMed
    Score: 0.175
  5. Parental history of substance use disorders (SUD) and SUD in offspring: a controlled family study of bipolar disorder. Am J Addict. 2014 Sep-Oct; 23(5):440-6.
    View in: PubMed
    Score: 0.147
  6. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder]. Z Kinder Jugendpsychiatr Psychother. 2021 Aug 16.
    View in: PubMed
    Score: 0.061
  7. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. Eur Addict Res. 2020; 26(4-5):223-232.
    View in: PubMed
    Score: 0.057
  8. Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. J Affect Disord. 2018 10 01; 238:244-249.
    View in: PubMed
    Score: 0.049
  9. The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria: A Double-Blind, Placebo-Controlled Trial of Naltrexone. J Clin Psychiatry. 2018 Mar/Apr; 79(2).
    View in: PubMed
    Score: 0.048
  10. Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone. J Clin Psychiatry. 2018 Jan/Feb; 79(1).
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.